In November 2023, we opened a new clinical unit in Ostrava (CZ). We have now received all necessary certificates for operation (including European GCP), and client audits are currently underway.

In addition, preparations for the first studies are progressing well, and we estimate that very first study will be initiated by the second quarter of this year.

To remind you of the festive atmosphere of the ribbon-cutting ceremony, we have prepared a video of the opening speech below.

The speech was held by Stephan Holl, CEO of Conscio Group, Roman Grunt, CEO of Quinta – Analytica, Jiří Juchelka, PI of Quinta – Analytica, and in the name of cooperation by Cyril Kučera, Deputy for Medical Care of the Ostrava City Hospital.

Additional News

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.

  • 8 června 2023

    Clinical Tips – Drug Interactions in Advanced Clinical Trial Design

    Drug interactions play a key role in the design of clinical trials. Learn how we investigate such interactions when conducting pharmacokinetic/bioequivalence studies and while offering end-to-end support throughout the process.

ALL POSTS